Abstract

Cytogenetic aberrations, such as chromosomal translocations, aneuploidy, and amplifications, are frequently detected in hematological malignancies. For many of the common autosomal aberrations, the mechanisms underlying their roles in cancer development have been well-characterized. On the contrary, although loss of a sex chromosome is observed in a broad range of hematological malignancies, how it cooperates in disease development is less understood. Nevertheless, it has been postulated that tumor suppressor genes reside on the sex chromosomes. Although the X and Y sex chromosomes are highly divergent, the pseudoautosomal regions are homologous between both chromosomes. Here, we review what is currently known about the pseudoautosomal region genes in the hematological system. Additionally, we discuss implications for haploinsufficiency of critical pseudoautosomal region sex chromosome genes, driven by sex chromosome loss, in promoting hematological malignancies. Because mechanistic studies on disease development rely heavily on murine models, we also discuss the challenges and caveats of existing models, and propose alternatives for examining the involvement of pseudoautosomal region genes and loss of a sex chromosome in vivo. With the widespread detection of loss of a sex chromosome in different hematological malignances, the elucidation of the role of pseudoautosomal region genes in the development and progression of these diseases would be invaluable to the field.

Highlights

  • Chromosomal abnormalities are frequently detected in cancers

  • Because PAR3 is only observed in approximately 2% of the general population, we focus on PAR1 and 2 in this review

  • While LOSS OF A SEX CHROMOSOME (LOS) is frequently observed in hematological malignancies, especially Acute myeloid leukemia (AML), there is a shortage of studies examining pseudoautosomal regions (PARs) genes in hematological disease development and progression

Read more

Summary

Introduction

Chromosomal abnormalities are frequently detected in cancers. These abnormalities include events such as aneuploidy, chromosomal duplications, deletions, inversions, and translocations. While LOS is frequently observed in hematological malignancies, especially AMLs, there is a shortage of studies examining PAR genes in hematological disease development and progression. Reduction in PPP2R3B gene dosage via LOS may result in reduced overall activity of PP2A, which could promote increased proliferation and confer survival advantage for leukemic cells.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call